Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors - Nature Medicine
- ️Zitvogel, Laurence
- ️Sun Sep 20 2009
References
Matzinger, P. The danger model: a renewed sense of self. Science 296, 301–305 (2002).
Savill, J., Dransfield, I., Gregory, C. & Haslett, C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2, 965–975 (2002).
Leadbetter, E.A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603–607 (2002).
Lau, C.M. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171–1177 (2005).
Chen, C.J. et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13, 851–856 (2007).
Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783–801 (2006).
Fritz, J.H., Ferrero, R.L., Philpott, D.J. & Girardin, S.E. Nod-like proteins in immunity, inflammation and disease. Nat. Immunol. 7, 1250–1257 (2006).
Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135–145 (2001).
Beutler, B. et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol. 24, 353–389 (2006).
Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59–73 (2008).
Obeid, M. et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 14, 1848–1850 (2007).
Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).
Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54–61 (2007).
Lotze, M.T. et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev. 220, 60–81 (2007).
Apetoh, L. et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059 (2007).
Sancho, D. et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458, 899–903 (2009).
Martinon, F. & Tschopp, J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 14, 10–22 (2007).
Di Virgilio, F. Liaisons dangereuses: P2X7 and the inflammasome. Trends Pharmacol. Sci. 28, 465–472 (2007).
Eisenbarth, S.C., Colegio, O.R., O'Connor, W., Sutterwala, F.S. & Flavell, R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122–1126 (2008).
Agostini, L. et al. NALP3 forms an IL-1β–processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319–325 (2004).
Poyet, J.L. et al. Identification of Ipaf, a human caspase-1–activating protein related to Apaf-1. J. Biol. Chem. 276, 28309–28313 (2001).
Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10, 417–426 (2002).
Sutterwala, F.S. et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24, 317–327 (2006).
Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
Mariathasan, S. et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228–232 (2006).
Ferrari, D. et al. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 176, 3877–3883 (2006).
Kanneganti, T.D. et al. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J. Biol. Chem. 281, 36560–36568 (2006).
Kanneganti, T.D. et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440, 233–236 (2006).
Ogura, Y., Sutterwala, F.S. & Flavell, R.A. The inflammasome: first line of the immune response to cell stress. Cell 126, 659–662 (2006).
Dinarello, C.A. Interleukin-1β, interleukin-18, and the interleukin-1β converting enzyme. Ann. NY Acad. Sci. 856, 1–11 (1998).
Brydges, S. & Kastner, D.L. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr. Top. Microbiol. Immunol. 305, 127–160 (2006).
Reginato, A.M. & Olsen, B.R. Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear? Curr. Opin. Rheumatol. 19, 134–145 (2007).
McIntyre, K.W. et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti–IL-1 receptor monoclonal antibody. J. Exp. Med. 173, 931–939 (1991).
Selzner, N. et al. Water induces autocrine stimulation of tumor cell killing through ATP release and P2 receptor binding. Cell Death Differ. 11 (Suppl 2), S172–S180 (2004).
Solle, M. et al. Altered cytokine production in mice lacking P2X7 receptors. J. Biol. Chem. 276, 125–132 (2001).
Srinivasula, S.M. et al. The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J. Biol. Chem. 277, 21119–21122 (2002).
Koebel, C.M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903–907 (2007).
Gu, B.J. et al. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J. Biol. Chem. 276, 11135–11142 (2001).
Sluyter, R., Shemon, A.N. & Wiley, J.S. Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1β release from human monocytes. J. Immunol. 172, 3399–3405 (2004).
Bours, M.J., Swennen, E.L., Di Virgilio, F., Cronstein, B.N. & Dagnelie, P.C. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112, 358–404 (2006).
Blankenstein, T. The role of tumor stroma in the interaction between tumor and immune system. Curr. Opin. Immunol. 17, 180–186 (2005).
Hinrichs, C.S., Gattinoni, L. & Restifo, N.P. Programming CD8+ T cells for effective immunotherapy. Curr. Opin. Immunol. 18, 363–370 (2006).
Ferrari, D., Chiozzi, P., Falzoni, S., Hanau, S. & Di Virgilio, F. Purinergic modulation of interleukin-1β release from microglial cells stimulated with bacterial endotoxin. J. Exp. Med. 185, 579–582 (1997).
Adachi, O. et al. Targeted disruption of the Myd88 gene results in loss of IL-1– and IL-18–mediated function. Immunity 9, 143–150 (1998).
Franchi, L., Kanneganti, T.D., Dubyak, G.R. & Nunez, G. Differential requirement of P2X7 receptor and intracellular K+ for caspase-1 activation induced by intracellular and extracellular bacteria. J. Biol. Chem. 282, 18810–18818 (2007).
Muruve, D.A. et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452, 103–107 (2008).
Pétrilli, V., Dostert, C., Muruve, D.A. & Tschopp, J. The inflammasome: a danger sensing complex triggering innate immunity. Curr. Opin. Immunol. 19, 615–622 (2007).
Krelin, Y. et al. Interleukin-1β–driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 67, 1062–1071 (2007).
Hagemann, T., Balkwill, F. & Lawrence, T. Inflammation and cancer: a double-edged sword. Cancer Cell 12, 300–301 (2007).
Greten, F.R. et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285–296 (2004).
Naugler, W.E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121–124 (2007).
Balkwill, F., Charles, K.A. & Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211–217 (2005).
Acknowledgements
We thank I. Couillin (CNRS) and A. Mignon (Cochin Hospital) for helpful discussion and for providing IL-1RA, R. Schreiber (Washington University School of Medicine) for monoclonal antibodies to IL-1α, IL-1β and IL-1R, H. Yang (Feinstein Institute for Medical Research) for antibody to HMGB1, H. Yagita (School of Medicine, Juntendo University) for the N2B2 antibody to mouse TRAIL, J.-C. Guéry (INSERM) for IL12rb2−/− mice, V. Dixit (Pennington Biomedical Research Center) for Pycard−/− mice, M. Albert (Pasteur Institute) for membrane-bound OVA–transfected mouse embryonic fibroblast cells, S. Forget and J. Bombled for access to the genomics platform, V. Vasseur and the Institut Gustave Roussy animal facility for breeding of transgenic mice, I. Martins for help in ATP release screening and A. Boissonnas (INSERM, Curie Institute) for providing OT1-GFP mice. We are deeply indebted to P. Arveux and S. Dabakuyo for useful help with the statistical analyses. The authors are supported by grants from the Ligue Nationale contre le Cancer (to L. Aymeric., G.K. and L.Z.), the Fondation pour la Recherche Médicale (to L. Apetoh., G.K., E.U., F.S. and L.Z.), the European Union (INFLACARE grant), the association for International cancer research (to G.K.) Cancéropôle Ile-de-France, Institut National du Cancer (L.Z., G.K.), Agence Nationale pour la Recherche (to G.K.), the European Molecular Biology Organization (L. Apetoh.), INSERM (A.T.), the National Health, Association pour la recherche sur le cancer RC (to G.M.), National Health and Medical Research Council of Australia, Cancer Council of Victoria, the China Scholarship Council (Y.M.) and the Leukemia Foundation (M.J.S., N.M.M. and N.M.H.). K.V. is the recipient of a European Respiratory Society Fellowship (number 605).
Author information
Author notes
François Ghiringhelli, Lionel Apetoh, Antoine Tesniere, Laetitia Aymeric, Mark J Smyth, Guido Kroemer and Laurence Zitvogel: These authors contributed equally to this work.
Authors and Affiliations
Institut National de la Santé et de la Recherche Médicale (INSERM), U805, Villejuif, France
François Ghiringhelli, Lionel Apetoh, Laetitia Aymeric, Yuting Ma, Carla Ortiz, Karim Vermaelen, Grégoire Mignot, Evelyn Ullrich, Fabrice André & Laurence Zitvogel
Institut Gustave Roussy, Villejuif, France
François Ghiringhelli, Lionel Apetoh, Antoine Tesniere, Laetitia Aymeric, Yuting Ma, Carla Ortiz, Karim Vermaelen, Theocharis Panaretakis, Evelyn Ullrich, Jean-Luc Perfettini, Frédéric Schlemmer, Ezgi Tasdemir, Fabrice André, Guido Kroemer & Laurence Zitvogel
AVENIR team INSERM CRI-866, Dijon, France
François Ghiringhelli
Centre Georges Francois Leclerc, Dijon, France
François Ghiringhelli & Grégoire Mignot
Université Paris-Sud, Villejuif, France
Lionel Apetoh, Antoine Tesniere, Laetitia Aymeric, Yuting Ma, Carla Ortiz, Karim Vermaelen, Theocharis Panaretakis, Evelyn Ullrich, Jean-Luc Perfettini, Frédéric Schlemmer, Ezgi Tasdemir, Fabrice André, Guido Kroemer & Laurence Zitvogel
Center for Neurological Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
Lionel Apetoh
INSERM, U848, Villejuif, France
Antoine Tesniere, Theocharis Panaretakis, Jean-Luc Perfettini, Frédéric Schlemmer, Ezgi Tasdemir & Guido Kroemer
Universidad de Chile, Facultad de Ciencias Químicas Farmacéuticas, Centro FONDAP Estudios Moleculares de la Célula, Santiago, Chile
Carla Ortiz
Department of Respiratory Medicine, Laboratory of Immunoregulation, Ghent University Hospital, Belgium
Karim Vermaelen
INSERM, U818, Institut Pasteur, Paris, France
Martin Uhl
UPR 2228-CNRS, Laboratoire de Régulation Transcriptionnelle et Maladies Génétiques, Biomédicale des Saints-Pères, Université Paris Descartes, Paris Cedex 06, France
Pierre Génin & Ahmet Civas
UMR6218, IEM, CNRS Transgenose Institute, Orleans, France
Bernhard Ryffel
UMR8619, CNRS, Université Paris, Orsay, France
Jean Kanellopoulos
Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
Jürg Tschopp
Centre René Huguenin, INSERM U735, St. Cloud, France
Rosette Lidereau
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Nicole M McLaughlin, Nicole M Haynes & Mark J Smyth
CICBT507, Villejuif, France
Laurence Zitvogel
Authors
- François Ghiringhelli
You can also search for this author in PubMed Google Scholar
- Lionel Apetoh
You can also search for this author in PubMed Google Scholar
- Antoine Tesniere
You can also search for this author in PubMed Google Scholar
- Laetitia Aymeric
You can also search for this author in PubMed Google Scholar
- Yuting Ma
You can also search for this author in PubMed Google Scholar
- Carla Ortiz
You can also search for this author in PubMed Google Scholar
- Karim Vermaelen
You can also search for this author in PubMed Google Scholar
- Theocharis Panaretakis
You can also search for this author in PubMed Google Scholar
- Grégoire Mignot
You can also search for this author in PubMed Google Scholar
- Evelyn Ullrich
You can also search for this author in PubMed Google Scholar
- Jean-Luc Perfettini
You can also search for this author in PubMed Google Scholar
- Frédéric Schlemmer
You can also search for this author in PubMed Google Scholar
- Ezgi Tasdemir
You can also search for this author in PubMed Google Scholar
- Martin Uhl
You can also search for this author in PubMed Google Scholar
- Pierre Génin
You can also search for this author in PubMed Google Scholar
- Ahmet Civas
You can also search for this author in PubMed Google Scholar
- Bernhard Ryffel
You can also search for this author in PubMed Google Scholar
- Jean Kanellopoulos
You can also search for this author in PubMed Google Scholar
- Jürg Tschopp
You can also search for this author in PubMed Google Scholar
- Fabrice André
You can also search for this author in PubMed Google Scholar
- Rosette Lidereau
You can also search for this author in PubMed Google Scholar
- Nicole M McLaughlin
You can also search for this author in PubMed Google Scholar
- Nicole M Haynes
You can also search for this author in PubMed Google Scholar
- Mark J Smyth
You can also search for this author in PubMed Google Scholar
- Guido Kroemer
You can also search for this author in PubMed Google Scholar
- Laurence Zitvogel
You can also search for this author in PubMed Google Scholar
Contributions
F.G., L. Aymeric., A.T., L. Apetoh., T.P., F.S., G.M., E.U., Y.M., N.M.M., N.M.H. and M.J.S. performed in vitro and in vivo experiments. C.O., E.T., P.G. and A.C. performed in vitro experiments. A.T. and T.P. performed immunofluorescence experiments. M.U., J.-L.P., B.R., J.K. and J.T. provided transgenic cells or mice and gave scientific advice. K.V., F.A., R.L., F.G. and A.T. performed the single nucleotide polymorphism analysis on cohorts of subjects with cancer. F.G., L. Apetoh., M.J.S. and A.T. prepared the figures and drafted the manuscript. G.K. and L.Z. designed the study and wrote the manuscript. M.J.S., G.K. and L.Z. all contributed equally to the design of the experiments and to the writing of the manuscript.
Corresponding authors
Correspondence to Guido Kroemer or Laurence Zitvogel.
Supplementary information
Rights and permissions
About this article
Cite this article
Ghiringhelli, F., Apetoh, L., Tesniere, A. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors. Nat Med 15, 1170–1178 (2009). https://doi.org/10.1038/nm.2028
Received: 16 July 2009
Accepted: 18 August 2009
Published: 20 September 2009
Issue Date: October 2009
DOI: https://doi.org/10.1038/nm.2028